193 related articles for article (PubMed ID: 17039230)
1. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.
Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S
Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230
[No Abstract] [Full Text] [Related]
2. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
3. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.
Benjamini O; Koren-Michowitz M; Amariglio N; Kroger N; Nagler A; Shimoni A
Leukemia; 2008 Oct; 22(10):1961-3. PubMed ID: 18685610
[No Abstract] [Full Text] [Related]
4. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
5. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation.
Steckel NK; Koldehoff M; Ditschkowski M; Beelen DW; Elmaagacli AH
Transplantation; 2007 Jun; 83(11):1518-20. PubMed ID: 17565328
[TBL] [Abstract][Full Text] [Related]
6. Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.
Torka P; Hahn T; Bertolo J; Liu H; Ross M; Paplham P; Jankowski A; Deeb G; Chen G; McCarthy P
Bone Marrow Transplant; 2015 Nov; 50(11):1480-2. PubMed ID: 26214139
[No Abstract] [Full Text] [Related]
7. Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation.
Wu YY; Hung HM; Chen TS; Chao TY; Ho CL
Leuk Res; 2008 Nov; 32(11):1783-6. PubMed ID: 18455791
[No Abstract] [Full Text] [Related]
8. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
Kröger N; Badbaran A; Holler E; Hahn J; Kobbe G; Bornhäuser M; Reiter A; Zabelina T; Zander AR; Fehse B
Blood; 2007 Feb; 109(3):1316-21. PubMed ID: 17018857
[TBL] [Abstract][Full Text] [Related]
10. Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation.
Lee JM; Ahn A; Min EJ; Lee SE; Kim M; Kim Y
Blood Cancer J; 2023 Jun; 13(1):97. PubMed ID: 37365186
[No Abstract] [Full Text] [Related]
11. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
12. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
Pasqualucci L; Li S; Meloni G; Schnittger S; Gattenlohner S; Liso A; Di Ianni M; Martelli MP; Pescarmona E; Foa R; Haferlach T; Skoda RC; Falini B
Leukemia; 2008 Jul; 22(7):1459-63. PubMed ID: 18200037
[No Abstract] [Full Text] [Related]
13. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
14. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.
Bornhäuser M; Mohr B; Oelschlaegel U; Bornhäuser P; Jacki S; Ehninger G; Thiede C
Leukemia; 2007 Aug; 21(8):1824-6. PubMed ID: 17476275
[No Abstract] [Full Text] [Related]
15. Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation.
Au WY; Fung A; Lam KY; Lie AK; Liang R; Kwong YL
Bone Marrow Transplant; 2006 Oct; 38(8):573-4. PubMed ID: 16953212
[No Abstract] [Full Text] [Related]
16. The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis.
Zhang SJ; Li JY; Zhang JF; Finn J; Lu H; Xu W; Qian SX; Wu HX
Leuk Res; 2009 Aug; 33(8):e116-8. PubMed ID: 19328546
[No Abstract] [Full Text] [Related]
17. Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.
Pieri L; Guglielmelli P; Bogani C; Bosi A; Vannucchi AM;
Leuk Res; 2008 Mar; 32(3):516-7. PubMed ID: 17706283
[No Abstract] [Full Text] [Related]
18. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
20. Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy.
Siebolts U; Lange T; Niederwieser D; Wickenhauser C
J Clin Pathol; 2010 Apr; 63(4):370-2. PubMed ID: 20354212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
